Protocol Ledger

NCT05270044 · Phase III · ACTIVE NOT RECRUITING

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Interventional Phase III clinical trial protocol NCT05270044 sponsored by Pierre Fabre Medicament in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-02 Enrollment: 815 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05270044
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)815 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05270044
Protocol FieldVerified Registry Value
NCT IdentifierNCT05270044
Consolidated Lead SponsorPierre Fabre Medicament
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment815 participants (ESTIMATED)
Registered Start Date2022-05-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05270044
Hospital Research SiteLocationSite Profile
Princess Alexandra HospitalWoolloongabba, AustraliaOpen Hospital Dossier ->
Box Hill HospitalBox Hill, AustraliaOpen Hospital Dossier ->
Austin HealthHeidelberg, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI